CASY-MSCCN Jobs

Leica Biosystems’ mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. We’re a global leader in cancer diagnostics with the most comprehensive portfolio from biopsy to diagnosis. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. Our associates know that every moment matters when it comes to cancer diagnostics. When you come to work, you’re helping develop solutions that enable accurate diagnoses to turn anxiety into answers. Join our diverse, global team of talented people, and be inspired to grow every day.

Leica Biosystems is proud to work alongside a community of six fellow Diagnostics Companies at Danaher. Together, we’re working at the pace of change to improve patient lives with diagnostic tools that address the world’s biggest health challenges.

The Senior Scientist II for Leica Biosystems is responsible for leading and supporting projects to develop and launch innovative new products to market. In addition, using initiative and critical thinking to solve complex problems and drive continuous improvements within the R&D department.

This position is part of the R&D Department located in Newcastle and will be on-site. At Leica Biosystems, our vision is to advance cancer diagnostics and improve lives.

You will be a part of the R&D team and report to the Technical Team Leader responsible for New Product Development. If you thrive in a fast paced environment and want to have a positive impact on future products —read on.

In this role, you will have the opportunity to:

• Apply expertise and knowledge to develop new products

• Lead functional teams and projects

• Provide guidance and mentorship to small project teams/other associates

• Contribute to strategic conversations

• Solve complex problems and recommend best practices to improve products and processes

The essential requirements of the job include:

• Ideally PhD level scientist, or research graduate with relevant experience

• A proven background immunohistochemistry gained in a clinical histopathology lab

• Experience of interpretation of IHC slides

• Demonstrable experience of assay optimisation/validation and understanding of regulatory requirements

• In depth knowledge of routine clinical histology lab workflow (fixation, microtomy, staining, interpretation) and clinically relevant biomarkers/panels

• Knowledge of cancer biology

• Demonstrable experience of technical critical thinking/problem solving around IHC assays

It would be a plus if you also possess previous experience in:

• Antibody/diagnostic assay development in academic or industrial setting

• Knowledge of current scientific opinion and market needs

• Performing and/or interpretation of in situ hybridisation

​ At Leica Biosystems we believe in designing a better, more sustainable workforce. We recognize the benefits of flexible, hybrid working arrangements for eligible roles and are committed to providing enriching careers, no matter the work arrangement. This position is eligible for a hybrid work arrangement in which you can work part-time at the Company location identified above and part-time remotely from your home. Additional information about this hybrid work arrangement will be provided by your interview team. Explore the flexibility and challenge that working for Leica Biosystems can provide.

At Danaher we bring together science, technology and operational capabilities to accelerate the real-life impact of tomorrow’s science and technology. We partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life. Our global teams are pioneering what’s next across Life Sciences, Diagnostics, Biotechnology and beyond. For more information, visit www.danaher.com.

At Danaher, we value diversity and the existence of similarities and differences, both visible and not, found in our workforce, workplace and throughout the markets we serve. Our associates, customers and shareholders contribute unique and different perspectives as a result of these diverse attributes.